Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemia

Leukemia

Volumn 15, Issue 5, 2001, Pages 764-771

  Visani, G ^a   Milligan, D ^b   Leoni, F ^c   Chang, J ^d   Kelsey, S ^e   Marcus, R ^f   Powles, R ^g   Schey, S ^h   Covelli, A ⁱ   Isidori, A ^a   Litchman, M ⁱ   Piccaluga, P P ⁱ   Mayer, H ⁱ   Malagola, M ⁱ   Pfister, C ⁱ  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^c UNIVERSITY OF FLORENCE   (Italy)

^d CHRISTIE HOSPITAL   (United Kingdom)

^e ROYAL LONDON HOSPITAL   (United Kingdom)

^f ADDENBROOKE S HOSPITAL   (United Kingdom)

^g ROYAL MARSDEN HOSPITAL   (United Kingdom)

^h GUY S HOSPITAL   (United Kingdom)

ⁱ NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Acute myeloid leukemia; Cytosine arabinoside; Mitoxantrone; Multidrug resistance; Reversing agents

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CYTARABINE; ETOPOSIDE; GLYCOPROTEIN P; MITOXANTRONE; VALSPODAR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; CANCER RECURRENCE; CANCER SURVIVAL; CEREBELLAR ATAXIA; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION FUNCTION; DRUG BLOOD LEVEL; DRUG TOLERABILITY; FEMALE; HEMATOLOGIC DISEASE; HUMAN; HYPERBILIRUBINEMIA; IN VITRO STUDY; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIDRUG RESISTANCE; PARESTHESIA; PHARMACOKINETICS; PHASE 1 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; REFRACTORY PERIOD;

EID: 0035001004     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402117     Document Type: Article

References (63)

1. Cellular resistance to actinomycin D in Chinese hamster cells in vitro: Cross-resistance, radioautographic and cytogenetic studies
2. Amplification of DNA sequences in human multidrug-resistant KB carcinoma cells
3. Isolation and expression of a complementary DNA that confers multidrug resistance
4. Expression of a multidrug resistance gene in human cancers
5. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants
6. Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines
7. Biochemistry of multidrug resistance mediated by the multidrug transporter
8. Multidrug resistance in human cancer
9. P-glycoprotein-mediated multidrug resistance in normal and neoplastic hematopoietic cells
10. Clinical relevance of P-glycoprotein expression in haematological malignancies
11. P-glycoprotein in adult hematologic malignancies
12. Relevance of mdr1 gene expression in acute myeloid leukemia and comparison of different diagnostic methods
13. Expression of the multidrug resistance gene product (P-glycoprotein) in myelodysplasia is associated with a stem cell phenotype
14. P-glycoprotein expression in patients with acute leukemia - Clinical relevance
15. MDR1 (multidrug resistance) gene expression in adult acute leukemia: Correlations with blast phenotype
16. Significantly lower P-glyco-protein expression in acute promyelocytic leukemia than in other types of acute myeloid leukemia: Immunological, molecular and functional analyses
17. The effect of MDR-1 gene expression on outcome in acute myeloblastic leukaemia
18. + acute myeloid leukemia cells
19. Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis
20. P-glycoprotein (P-170) and CD34 expression in adult acute myeloid leukemia (AML)
21. P-glycoprotein expression on acute myeloid leukaemia blasts cells at diagnosis predicts response to chemotherapy and survival
22. Expression of the multidrug transporter, P-glycoprotein, in acute leukemia cells and correlation to clinical drug resistance
23. Multidrug resistance (mdr1) gene expression in adult acute leukemias: Correlations with treatment outcome and in vitro drug sensitivity
24. MDR1 gene expression and treatment outcome in acute myeloid leukemia
25. P-glycoprotein expression as unfavorable prognostic factor in acute myeloid leukemia
26. In vitro drug sensitivity of leukemic progenitors and P-glycoprotein expression in adult myeloid leukemia: Correlation with induction treatment outcome
27. Expression of multidrug resistance-associated protein (MRP) and multidrug resistance (MDR1) genes in acute myeloid leukemia
28. Acute myeloid leukemia in the elderly: Assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy
29. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glicoprotein, MRP1, and LRP in acute myeloid leukemia
30. Treatment of refractory and relapsed acute myeloid leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar)
31. Treatment of poor prognosis AML patients using PSC833 (Valspodar) plus mitoxantrone, etoposide, and cytarabine (PSC-MEC)
32. Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myeloid leukemia
33. Modulation of anthracycline resistance in poor-risk acute myeloid leukemia (AML) with SDZ PSC-833: Results of a phase I/II multicenter study
34. Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid Cancer and Leukemia Group B Study 9420
35. A phase I study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia (AML) using mitoxantrone, etoposide, and the MDR modulator PSC 833: A Southwest Oncology Group study 9617
36. Dose-finding study of PSC 833, a novel MDR reversing agent, with daunorubicin and ara-C in untreated elderly patients with acute myeloid leukemia
37. Phase I study of paclitaxel in combination with a multidrug resistance modulator, PSC 833 (Valspodar), in refractory malignancies
38. Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma: A phase I study
39. Phase I study of the chemosen-sitizer SDZ PSC 833 in combination with VAD chemotherapy to reverse multidrug resistance
40. Restoration of daunomycin retention in multidrug-resistant P388 cells by submic-romolar concentrations of SDZ PSC 833, a nonimmunosuppressive cyclosporin derivative
41. Cyclosporins as drug resistance modifiers
42. Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin
43. Mitoxantrone, etoposide, and intermediate-dose cytarabine: An effective and tolerable regimen in the treatment of refractory acute myeloid leukemia
44. Mitoxantrone, etoposide, and intermediate-dose Ara-C: An effective regimen for poor risk acute myeloid leukemia
45. MEC (mitoxantrone, etoposide, and intermediate-dose cytarabine): An effective induction regimen for previously untreated acute non-lymphocytic leukemia
46. Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: Long-term follow-up of the etoposide, mitoxantrone, and cytarabine-86 trial
47. Pharmacologic approaches to reversing multidrug resistance
48. Proposed revised criteria for the classification of acute myeloid leukemia
49. Report of the National Cancer Institute sponsored workshop on definition of diagnoses and response in acute myeloid leukemia
50. Regrowth resistance in leukemias and lymphomas. The need for a new system to classify system failures and new approaches for treatment
51. The pharmacokinetics and bioavailability of a new chemosensitizer, SDZ PSC833, in patients with advanced cancer
52. Quantification of teniposide in human serum by high-performance liquid chromatography with electro-chemical detection
53. Analysis of the interactions of SDZ PSC 833 ([3′keto-Bmt1]-Val2]-cyclosporine), a multidrug resistance modulator, with P-glycoprotein
54. A stratification system for evaluating and selecting therapies in patients with relapsed or primary refractory acute myeloid leukemia
55. Treatment of relapsed acute myeloid leukemia with idarubicin and intermediate-dose cytarabine
56. Etoposide: An update
57. Bioequivalence assessment of etoposide phosphate and etoposide using pharmacodynamic and traditional pharmacokinetic parameters
58. Mitoxantrone: A review of its pharmacological properties and use in acute nonlymphoblastic leukemia
59. Enhancement of daunorubicin accumulation, retention, and cytotoxicity by verapamil or cyclosporin A in blasts cells from patients with previously untreated acute myeloid leukaemia
60. Correlation of multidrug resistance (MDR1) protein expression with functional dye/drug efflux in acute myeloid leukaemia by multiparameter flow cytometry: Identification of discordant MDR-/efflux+ and MDR1+/efflux- cases
61. Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: A randomized multicenter study
62. Quinine improves the results of intensive chemotherapy in myelodysplastic syndromes expressing P glycoprotein: Results of a randomized study
63. Quinine improves results of intensive chemotherapy (IC) in myelodysplastic syndromes (MDS) expressing P-glycoprotein (PGP). Updated results of a randomized study